Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 1 Interventional

Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC

ClinicalTrials.gov ID: NCT07938463

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07938463. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 4:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

TAP-ALK: A Phase I/II Study of TNG462 in Combination With Lorlatinib in MTAP-Deleted, ALK-Rearranged NSCLC Following Progression on Prior TKI Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

TAP-ALK is a DF/HCC investigator-sponsored interventional study of TNG462 (vopimetostat) in combination with lorlatinib for participants with MTAP-deleted, ALK-rearranged non-small cell lung cancer (NSCLC) following progression on prior tyrosine kinase inhibitor (TKI) therapy. The study is being conducted under IND 183798 and plans to enroll 30 participants.

Study identification

NCT ID
NCT07938463
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 1
Enrollment
30 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2027 (Estimated)
Primary completion
Nov 30, 2027 (Estimated)
Completion
Jun 30, 2028 (Estimated)
Last update posted
Nov 16, 2026

2027 – 2028

United States locations

U.S. sites
2
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Brigham and Women's Hospital Boston Massachusetts 02215 —
Dana Farber Cancer Institute Boston Massachusetts 02215 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07938463, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 16, 2026 · Synced Nov 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.